201 Mission Street Suite 2375
111 articles with Jaguar Health
Jaguar Health Subsidiary Receiving Preclinical Services from the National Institute of Allergy and Infectious Diseases for New Preclinical Study Initiated July 21, 2020 for Lechlemer Plant-based Drug Candidate for Cholera
Jaguar Health, Inc. (NASDAQ:JAGX) announced today that the 28-day preclinical toxicology and safety study in rats began yesterday to support development of lechlemer, the second generation, plant-based anti-secretory drug candidate of Napo Pharmaceuticals
Jaguar Health, Inc. (NASDAQ:JAGX) (''Jaguar'' or the ''Company'') today announced the voting results from the Special Meeting of Stockholders of the Company (the "Special Meeting") that was held on July 21, 2020.
FDA Invites Jaguar Health to Expedite Submission of Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Chemotherapy-induced Diarrhea in Dogs
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that it has submitted to the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) the second-to-last required technical section to support approval of Jaguar's oral plant-based drug candidate Canalevia™
Jaguar Health Subsidiary Napo Pharmaceuticals Completes Filing of Investigational New Drug Application for Crofelemer (Mytesi) for Symptomatic Relief of Cancer Therapy‑Related Diarrhea
A significant proportion of patients undergoing cancer therapy experience diarrhea.
Jaguar Health, Inc. announced today that it has submitted to the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) the final major regulatory filing to support approval of its oral plant-based drug candidate Canalevia™
Canalevia would be first and only FDA-approved plant-based medicine for working dogs that suffer from diarrhea
On World Rainforest Day, Jaguar Health Reinforces Commitment to Amazon Rainforest and Sustainable Harvesting Programs for Plant-based Pharmaceuticals
Jaguar Health, Inc.'s (NASDAQ:JAGX) chief of sustainability and ethnobotanist Steven King, Ph.D. was featured on Forest Trends' Viewpoints, discussing the ancient and powerful medicinal knowledge of Indigenous peoples and local communities in the Amazon Rainforest, the importance of understanding, respecting and conserving this vast body of wisdom along with the rainforests, and the pioneering fair-trade tree-to-bottle development of Mytesi
Jaguar Health, Inc. announced the voting results from the Annual Meeting of Stockholders of the Company that was held on May 15, 2020.
Jaguar Health Enters Share Purchase Agreement for 2 Million Shares and Common Stock Purchase Agreement Relating to a 10 Million Share Equity Line Offering With L2 Capital, LLC
Net proceeds to the Company from the Registered Direct Offering are approximately $0.49 million, which Jaguar intends to use for the ongoing commercialization of Mytesi, the Company’s lead prescription drug product, and for working capital and general corporate purposes.
Year-to-Date Gross Sales for Mytesi, the FDA-Approved Human Prescription Drug Product of Jaguar Health’s Wholly-Owned Subsidiary, Napo Pharmaceuticals, Total $2.8M
The average monthly Mytesi sales from August through October of this year increased over 50% relative to average monthly Mytesi® sales that took place from January through July of 2017.
The call is being hosted to review year-to-date sales figures for Jaguar and Napo Pharmaceuticals.
Dr. Roscoe M. Moore Jr., DVM, MPH, Ph.D., DSc Joins Napo Pharmaceuticals Scientific Advisory Board for HIV for Mytesi, Napo's FDA-Approved Human Prescription Drug
Napo’s HIV Scientific Advisory Board will focus primarily on physician education, and community and global awareness regarding the importance and availability of solutions for neglected comorbidities.